7-Day Deadline Reminder: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 02/01/22
RVNC Alert: Thornton Law Firm Reminds Revance Therapeutics Investors of Securities Class ActionNewsfile Corp • 02/01/22
RVNC Upcoming Deadline: Bronstein, Gewirtz & Grossman, LLC, a Nationally Recognized Firm, Reminds Revance Therapeutics, Inc. Investors of Class Action and Lead Plaintiff Deadline: February 8, 2022Newsfile Corp • 01/31/22
SECURITIES CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Reminds RVNC Investors of Upcoming Deadline and Urges Investors with Substantial Losses to Contact the FirmPRNewsWire • 01/30/22
(RVNC) DEADLINE: Did You Suffer a Substantial Loss? Contact Johnson Fistel About Leading Revance Therapeutics Class Action LawsuitNewsfile Corp • 01/29/22
Upcoming Deadline Reminder: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 01/28/22
RVNC SHAREHOLDER ALERT: Jakubowitz Law Reminds Revance Shareholders of a Lead Plaintiff Deadline of February 8, 2022PRNewsWire • 01/28/22
Investor Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against Revance Therapeutics, Inc. (RVNC)Newsfile Corp • 01/28/22
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Revance Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 8, 2022 - RVNCPRNewsWire • 01/27/22
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Revance Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 8, 2022 - (RVNC)PRNewsWire • 01/26/22
Shareholder Action Alert: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 01/26/22
ROSEN, A LEADING LAW FIRM, Encourages Revance Therapeutics, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important February 8 Deadline in Securities Class Action - RVNCPRNewsWire • 01/26/22
Investor Action Reminder: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 01/25/22
Shareholder Action Notice: The Schall Law Firm Encourages Investors in Revance Therapeutics, Inc. with Losses of $100,000 to Contact the FirmNewsfile Corp • 01/24/22
UPCOMING DEADLINE: Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RVNCNewsfile Corp • 01/24/22
Revance Therapeutics Inc. News: Berger Montague Investigates Securities Fraud Allegations Against Revance Therapeutics Inc. (RVNC); Lead Plaintiff Deadline is February 8, 2022Newsfile Corp • 01/24/22
Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline for Securities Fraud Class Action Lawsuit Filed Against Revance Therapeutics, Inc.Newsfile Corp • 01/23/22
INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That a Securities Class Action Lawsuit Has Been Filed on Behalf of Revance Therapeutics, Inc. (RVNC) Investors and Encourages Investors to Contact the Firm Before February 8, 2022Business Wire • 01/21/22
Thornton Law Firm Reminds Revance Therapeutics (RVNC) Investors of Securities Class ActionNewsfile Corp • 01/21/22
RVNC LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Revance Therapeutics, Inc.Newsfile Corp • 01/21/22
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Revance Therapeutics, Inc. a Class Action Lawsuit and a Lead Plaintiff Deadline of February 8, 2022 - RVNCPRNewsWire • 01/20/22
SHAREHOLDER ALERT: Kessler Topaz Meltzer & Check, LLP Reminds RVNC Investors of Securities Fraud Class Action Lawsuit Filed On Their BehalfPRNewsWire • 01/20/22
RVNC CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Announces to Revance Therapeutics, Inc. Investors of Deadline in Securities Fraud Class Action LawsuitNewsfile Corp • 01/19/22
Revance Receives Clarity on Path to Resubmission of the BLA for DaxibotulinumtoxinA for Injection Following Type A Meeting with FDABusiness Wire • 01/18/22
